This pandemic has changed everyone’s lifestyle and affected people around the world. It not only made a difference in lifestyle but also brought a change in our physical and psychological well being. This is also drastically changed the way many people function and interact as social isolation has forced them to step away from regular schedules.
The common words we have used during the pending are “stay safe, stay home” and COVID-19. According to the World Health Organisation around 170 COVID-19 vaccines are in development. And the companies that are developing the COVID vaccines are promising that the vaccine will protect from the deadly virus and will be effective and allow them to go back to work and college.
Some of the COVID-19 vaccines are in the final stage of testing which depends on the result, some companies claiming that their vaccine could be greenlighted for use as soon as this year. In early testing, the vaccine successfully produced immune responses in humans with only minor side effects. A Phase 3 trial enrolling 30,000 subjects in the U.S. began in August. Other late-stage trials are underway with several thousand volunteers in the U.K., Brazil, and South Africa.
The vaccine which is developed by the University of Oxford and AstraZeneca PLC is starting the final round of testing. Some of the vaccines that showing promise in early trials are failing during the final rounds.
Johnson & Johnson is already developing a vaccine that uses a weakened form of a common cold virus, known as an adenovirus. A single dose of this vaccine provoked a strong immune response in early animal testing. The company plans to launch by late September a 60,000-person global study, which could be the largest late-stage clinical trial of a Covid-19 vaccine. The company will carry out the study at nearly 180 locations in the U.S. and eight other countries where transmission rates are high, including Brazil, Chile, and South Africa.
American Company Novavax Inc. is making a vaccine that consists of two shots given 21 days apart that deliver proteins resembling the spike jutting out from the new coronavirus. Researchers hope the proteins will trigger the production of antibodies and immune cells that can fight off the coronavirus.
The shots also contain a component, called an adjuvant, to boost the immune response. In Phase 1 testing, the vaccine was generally well-tolerated and produced promising numbers of antibodies. Phase 2 testing began in August, and the company has said Phase 3 could start in September. With a production capacity estimated 100 million doses for use in the U.S., with delivery beginning by the end of this year, it seems to be the best fit for the current situation. Plans to manufacture for other countries.